The main objective of this national study is to evaluate the virological success of long-acting antiretroviral therapy combining cabotegravir and lenacapavir. The study involves patients who have been receiving this treatment for one year or those for whom the physician decides to initiate it. It also aims to evaluate the tolerability of the treatment and changes in the participants' immunovirological profile during follow-up.
Age ≥18 years
HIV-1 infection
Patients who started taking cabotegravir combined with lenacapavir between July 2024 and the one-year follow-up, or who are due to start taking the CAB/LEN combination.
Patients who are due to start the CAB/LEN combination following a medical decision.
Participants' objection to the use of follow-up data
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Lead sponsor
INSERM UMR S 1136
Collaborator
ANRS, Emerging Infectious Diseases
Collaborator